Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2420499122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Taylor G Eggertsen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Machine Learning, Escitalopram, Cardiomegaly. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
Cardiomyocyte hypertrophy is a key clinical predictor of heart failure. High-throughput and AI-driven screens have the potential to identify drugs and downstream pathways that modulate cardiomyocyte hypertrophy. Here, we developed LogiRx, a logic-based mechanistic machine learning method that predicts drug-induced pathways. We applied LogiRx to discover how drugs discovered in a previous compound screen attenuate cardiomyocyte hypertrophy. We experimentally validated LogiRx predictions in neonatal cardiomyocytes, adult mice, and two patient databases. Using LogiRx, we predicted antihypertrophic pathways for seven drugs currently used to treat noncardiac disease. We experimentally validated that escitalopram (Lexapro) and mifepristone inhibit hypertrophy of cultured cardiomyocytes in two contexts. The LogiRx model predicted that escitalopram prevents hypertrophy through an “off-target” serotonin receptor/PI3Kγ pathway, mechanistically validated using additional investigational drugs. Further, escitalopram reduced cardiomyocyte hypertrophy in a mouse model of hypertrophy and fibrosis. Finally, mining of both FDA and University of Virginia databases showed that patients with depression on escitalopram have a lower incidence of cardiac hypertrophy than those prescribed other serotonin reuptake inhibitors that do not target the serotonin receptor. Mechanistic machine learning by LogiRx discovers drug pathways that perturb cell states, which may enable repurposing of escitalopram and other drugs to limit cardiac remodeling through off-target pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908.
- Division of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045-2507.
- Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA 22908.
ORCID-Profile: Taylor G Eggertsen, Elizabeth J Hardy, Matthew J Wolf, Jeffrey J Saucerman
Förderung
- NHLBI NIH HHS
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Eggertsen, T. G., Travers, J. G., Hardy, E. J., Wolf, M. J., McKinsey, T. A., & Saucerman, J. J. (2025). Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2420499122
Vancouver
Eggertsen TG, Travers JG, Hardy EJ, Wolf MJ, McKinsey TA, Saucerman JJ. Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2420499122
BibTeX
@article{Eggertsen2025,
author = {Eggertsen, Taylor G and Travers, Joshua G and Hardy, Elizabeth J and Wolf, Matthew J and McKinsey, Timothy A and Saucerman, Jeffrey J},
title = {Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2420499122}
}
EUVIMED